Stryker Corporation
SYK
$276.43
-8.81%
Stryker Corporation is a leading medical technology company that designs, manufactures, and markets a broad portfolio of medical devices, including orthopedic implants, surgical equipment, neurovascular products, and hospital beds. As one of the top three players in reconstructive orthopedics and the leader in operating room equipment, Stryker holds a strong competitive position in the healthcare sector. The current investor narrative centers on the company's strategic acquisitions, such as the recent Amplitude Vascular Systems deal to enhance its peripheral vascular offerings, and its ability to sustain growth amid a challenging market environment that has seen its stock decline significantly over the past year.…
SYK
Stryker Corporation
$276.43
Related headlines
Investment Opinion: Should I buy SYK Today?
Based on the analysis, SYK is rated a Hold. The stock is trading at $303.13, with an average analyst target of $382.72, implying 26.3% upside, but the recent downtrend and decelerating growth warrant caution. The forward PE of 18.09x is below the industry average of 22x, suggesting potential value if earnings growth materializes, but the trailing PE of 41.4x and PEG of 5.16 indicate overvaluation on current earnings. The company's strong balance sheet, with a current ratio of 1.89 and FCF of $4.57 billion, provides a cushion, but revenue growth of only 2.63% YoY is insufficient to justify a premium valuation. This Hold would upgrade to Buy if the stock stabilizes above $320 and revenue growth accelerates above 5%, or downgrade to Sell if the stock breaks below $281 and operating margins continue to compress. Overall, SYK is fairly valued on a forward basis but overvalued on trailing metrics, making it a cautious hold for now.
Sign up to view all
SYK 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the forward valuation appears attractive and analysts are bullish, the decelerating revenue growth and negative price momentum create uncertainty. The stock's high trailing PE and PEG ratio suggest that current earnings do not support the valuation, but the forward PE implies the market expects a significant earnings jump. If the company can deliver on growth expectations and stabilize margins, the stock could recover, but the risk of continued underperformance remains. Upgrades to bullish would require evidence of accelerating revenue growth and margin expansion, while downgrades to bearish would be triggered by further deterioration in fundamentals or a break below the 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $382.72 and implied upside of +38.5% versus the current price.
Average Target
$382.72
0 analysts
Implied Upside
+38.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 25 analysts, with a consensus recommendation of 'buy' and a mean rating of 1.68 (where 1 is strong buy and 5 is sell). The average target price is $382.72, implying an upside of 26.3% from the current price of $303.13. The distribution includes 10 analysts with actions such as Outperform, Overweight, or Buy, and one Hold, indicating a bullish sentiment. The target price range is from a low of $315.00 to a high of $465.00, with the high target suggesting a 53.4% upside, likely assuming successful integration of acquisitions and margin expansion. The low target of $315.00 still implies a 3.9% upside, reflecting limited downside risk. Recent ratings have been stable, with no downgrades, and BMO Capital upgraded from Market Perform to Outperform in July 2026, signaling positive momentum. The wide spread between low and high targets (48% difference) indicates moderate uncertainty, but the overall bullish consensus suggests analysts see the current pullback as a buying opportunity.
Drowning in data?
Find the real signal!
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: strong fundamentals with a healthy balance sheet, high gross margins, and a bullish analyst consensus, but offset by a steep stock decline, decelerating revenue growth, and margin compression. The bull case rests on the forward PE being at a discount to peers and the potential for acquisitions to drive growth, while the bear case highlights the stock's persistent underperformance and high trailing valuation. Currently, the bearish technicals and growth deceleration appear to outweigh the valuation appeal, but the analyst consensus and forward earnings expectations suggest a potential turnaround. The key tension is whether the market's pessimistic view is justified or if the stock is oversold, with the resolution likely hinging on the company's ability to accelerate revenue growth and stabilize margins in the coming quarters.
Bullish
- Analyst consensus bullish with 26% upside: 25 analysts rate SYK a 'buy' with a mean rating of 1.68 and an average target price of $382.72, implying 26.3% upside from the current price of $303.13. The low target of $315 still offers 3.9% upside, indicating limited downside risk.
- Forward PE at 18x suggests undervaluation: The forward PE of 18.09x is 18% below the industry average of 22x, while the trailing PE of 41.4x is at a premium. This gap implies the market expects significant earnings growth, making the stock attractive on a forward basis if growth materializes.
- Strong balance sheet and liquidity: Stryker has a debt-to-equity ratio of 0.73 and a current ratio of 1.89, indicating a healthy balance sheet. Free cash flow for the trailing twelve months was $4.57 billion, comfortably covering capital expenditures and dividends.
- Strategic acquisition to drive growth: The completion of the Amplitude Vascular Systems acquisition in May 2026 adds next-generation IVL technology to the peripheral vascular portfolio, positioning Stryker for growth in a key medical device market and diversifying revenue streams.
Bearish
- Stock in steep downtrend, -23% in 1 year: SYK has declined 23.13% over the past year and 16.85% over six months, underperforming the S&P 500 by 41.8 percentage points. The stock is near its 52-week low of $281, reflecting persistent selling pressure and negative momentum.
- Revenue growth decelerating to 2.6%: Q1 2026 revenue grew only 2.63% YoY to $6.02 billion, down from earlier quarters (Q4 2025 revenue was $7.17 billion). This deceleration raises concerns about the company's ability to sustain growth in a competitive market.
- Operating margin compressed sharply: Operating margin fell to 15.55% in Q1 2026 from 27.35% in Q4 2025, reflecting higher expenses. This volatility in margins could signal cost pressures or one-time charges, impacting profitability.
- High trailing PE and PEG ratio: The trailing PE of 41.4x is 88% above the industry average of 22x, and the PEG ratio of 5.16 suggests the stock is overvalued relative to its growth rate. This premium could lead to multiple compression if growth disappoints.
SYK Technical Analysis
Stryker's stock is in a clear downtrend, with a 1-year price change of -23.13% and a 6-month decline of -16.85%. The current price of $303.13 is near the lower end of its 52-week range, sitting at approximately 12.6% above the 52-week low of $281.00 and 23.5% below the high of $396.37. This positioning near the lows suggests bearish sentiment and potential value opportunity, but also reflects persistent selling pressure.
Beta
0.77
0.77x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$275-$396
Price range past year
Annual Return
-29.7%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -18.5% | -0.9% |
| 3m | -10.5% | +5.6% |
| 6m | -18.0% | +15.0% |
| 1y | -29.7% | +18.1% |
| ytd | -20.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue growth has been modest but positive, with the most recent quarter (Q1 2026) showing revenue of $6.02 billion, a 2.63% increase year-over-year. This growth is decelerating compared to earlier quarters, as Q4 2025 revenue was $7.17 billion (up from $6.44 billion in Q4 2024), and Q3 2025 revenue was $6.06 billion. The MedSurg segment generated $3.21 billion and Orthopaedics $2.81 billion in the latest quarter, indicating balanced contributions. The company's profitability remains solid, with a gross margin of 63.29% and a net margin of 12.38% in Q1 2026, though operating margin compressed to 15.55% from 27.35% in Q4 2025, reflecting higher expenses. Net income for Q1 2026 was $745 million, down from $849 million in Q4 2025, but up from $654 million in Q1 2025. Stryker's balance sheet is healthy, with a debt-to-equity ratio of 0.73 and a current ratio of 1.89, indicating strong liquidity. Free cash flow for the trailing twelve months was $4.57 billion, and the company generated $581 million in operating cash flow in Q1 2026, sufficient to cover capital expenditures of $166 million and dividends of $337 million, though debt repayment of $1 billion reduced cash reserves.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given Stryker's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 41.40x, while the forward PE is 18.09x, implying that the market expects significant earnings growth, with the forward multiple suggesting a 56.3% discount to trailing. This gap indicates high growth expectations embedded in the current price. Compared to the industry average PE of 22x (based on available data), Stryker trades at a premium of 88% on a trailing basis, but on a forward basis, it is at a discount of 18%, reflecting the market's anticipation of accelerated earnings. Historically, Stryker's PE has ranged from 23x to 78x over the past few years, with the current trailing PE of 41.4x near the middle of that range, suggesting it is not at extreme levels. The PS ratio of 5.35x is below the historical average of around 20x, indicating a relatively lower valuation on sales, which may be attractive if growth resumes.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high trailing PE of 41.4x, which could compress if earnings growth slows, and a PEG ratio of 5.16 indicating the stock is expensive relative to its growth rate. Operating margin volatility, dropping from 27.35% in Q4 2025 to 15.55% in Q1 2026, suggests potential cost pressures or one-time charges that could impact profitability. While the debt-to-equity ratio of 0.73 is manageable, the company's $1 billion debt repayment in Q1 2026 reduced cash reserves, and free cash flow of $4.57 billion TTM may be strained if acquisitions continue.
FAQ
The key risks include financial risks such as a high trailing PE of 41.4x and a PEG ratio of 5.16, which could lead to multiple compression if earnings growth disappoints. Operational risks include decelerating revenue growth of 2.63% YoY and operating margin compression from 27.35% in Q4 2025 to 15.55% in Q1 2026. Competitive risks include intense competition in the medical device market, which could pressure pricing and market share. Macro risks include the stock's beta of 0.768, indicating moderate sensitivity to market movements, and the potential for a broader market downturn to exacerbate the stock's decline. The most severe risk is a break below the 52-week low of $281, which could trigger further selling.
The 12-month forecast for SYK is mixed, with a base case probability of 50% for a price range of $315 to $382.72, a bull case probability of 25% for a range of $382.72 to $465, and a bear case probability of 25% for a range of $281 to $315. The base case assumes revenue growth of 3-4% and stable margins, leading to a price around the average analyst target of $382.72. The bull case requires accelerated growth and margin expansion, while the bear case involves further deterioration. The most likely scenario is the base case, with the stock trading in a range as the market awaits evidence of growth acceleration. The key assumption is that the company can maintain its competitive position and execute on its growth initiatives.
SYK is overvalued on a trailing basis with a PE of 41.4x, which is 88% above the industry average of 22x, but undervalued on a forward basis with a PE of 18.09x, which is 18% below the industry average. This discrepancy implies the market expects significant earnings growth, as the forward PE suggests a 56.3% discount to trailing. The PS ratio of 5.35x is below the historical average of around 20x, indicating a relatively lower valuation on sales. The PEG ratio of 5.16 suggests the stock is expensive relative to its growth rate, but if the company can achieve the expected earnings growth, the valuation could be justified. Overall, the market is pricing in a strong recovery, making the stock fairly valued if growth accelerates, but overvalued if it does not.
SYK is a good buy for investors with a long-term horizon who believe in the company's growth prospects, given the 26.3% upside to the average analyst target of $382.72. However, the stock is in a downtrend, down 23% over the past year, and revenue growth is only 2.63%, so it may not be suitable for short-term traders. The forward PE of 18.09x is below the industry average, suggesting value if earnings growth materializes, but the trailing PE of 41.4x indicates overvaluation on current earnings. The biggest risk is a continued deceleration in growth, which could push the stock lower. Overall, it is a buy for patient investors, but a hold for those seeking immediate returns.
SYK is more suitable for long-term investment due to its stable business model, strong free cash flow of $4.57 billion, and dividend yield of 0.96%, which provides some income. The stock's beta of 0.768 indicates lower volatility than the market, but the recent 23% decline over the past year shows it can still experience significant drawdowns. Short-term trading is risky given the negative momentum and decelerating growth, but long-term investors could benefit from the company's strategic acquisitions and potential for earnings growth. A minimum holding period of 3-5 years is recommended to allow the company to execute on its growth initiatives and for the market to recognize the value. The stock is not suitable for investors seeking quick gains or those with a low risk tolerance.
